Related Experiment Videos
Successful thrombolytic therapy for massive pulmonary embolism.
M Onuigbo1, M Cuffy-Hallam, A Mangano
1Department of Internal Medicine, Greater Baltimore Medical Center, MD 21204, USA.
Southern Medical Journal
|March 23, 2000
Summary
Thrombolytic therapy using tissue plasminogen activator (tPA) shows promise for severe pulmonary embolism (PE) with right ventricular dysfunction, even without shock. This approach may improve survival in select PE patients, warranting further investigation.
Area of Science:
- Cardiology
- Pulmonary Medicine
- Pharmacology
Background:
- Pulmonary embolism (PE) management is evolving.
- Thrombolytic therapy's role in massive PE with cardiogenic shock is suggested by small studies but lacks large-scale evidence.
- Its use in PE with right ventricular dysfunction (RVD) but without hemodynamic collapse is controversial.
Observation:
- Successful use of tissue plasminogen activator (tPA) in a life-threatening PE case with RVD but no overt cardiovascular collapse is reported.
- This case provides evidence supporting thrombolytic therapy in this specific PE patient group.
Findings:
- Tissue plasminogen activator (tPA) can be effectively used in managing severe pulmonary embolism (PE) with right ventricular dysfunction (RVD) in patients not experiencing overt hemodynamic collapse.
- This suggests potential benefits beyond current established indications.
Implications:
- Broadening thrombolytic therapy use to PE patients with RVD but without cardiogenic shock may be beneficial, particularly in younger individuals.
- This approach is considered worth the associated risks, meriting further clinical consideration and research.